首页> 外文OA文献 >Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

【2h】

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

机译：LixiLan的可滴定固定比例胰岛素口服组合物的可控固定比例组合在口服药物控制不充分的2型糖尿病中的作用与胰岛素甘草碱和Lixisenatide单组分的比较：LixiLan-O随机试验。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Rosenstock, J.; Aronson, R.; Grunberger, G.; Hanefeld, M.; Piatti, P.; Serusclat, P.; Cheng, X.; Zhou, T.; Niemoeller, E.; Souhami, E.; Davies, Melanie; LixiLan-O Trial Investigators;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial [J] . Rosenstock Julio, Aronson Ronnie, Grunberger George, Diabetes care . 2016,第11期

机译：LixiLan的可滴定固定比例胰岛素对照与口服药物控制不充分的2型糖尿病的利西拉肽，利西拉肽和利西拉肽单组分的可计量固定比例组合的益处：LixiLan-O随机试验
2. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents [J] . Davies Melanie J., Leiter Lawrence A., Guerci Bruno, Diabetes, obesity & metabolism . 2017,第12期

机译：基线糖化血红蛋白，糖尿病持续时间和体重指数对莱西兰 - o试验中可滴注的固定比组合（Iglarllixi）与胰岛素狼生物和Lixisenatide单一组分的肝脏试验中的临床结果对脑兰 - o试验的影响
3. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial [J] . Rosenstock Julio, Diamant Michaela, Aroda Vanita R., Diabetes care . 2016,第9期

机译：二甲双胍单药治疗控制不佳的2型糖尿病患者利西拉来定与胰岛素甘草碱的可滴定固定比例联合利西拉来的疗效和安全性：利西兰概念验证的随机试验
4. TITLE: 6-month administration of Oral Insulin at Lunchtime in Juvenile Type-1 DM Subjects on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin [C] . Jaime Guevara-Aguirre, Marco Guevara-Aguirre, Jeannette Saavedra, Controlled Release Society Annual Meeting and Exposition . 2007

机译：标题：午餐时间为1型DM少年受试者接受基础甘草碱胰岛素和早餐前和晚餐前常规胰岛素的口服胰岛素治疗，为期6个月
5. The relationship between the emotional burden of Type 2 Diabetes and glycemic control and differences in emotional burden and glycemic control among individuals treated with oral antidiabetic agents, combination therapy, incretin mimetic, and insulin [D] . Douaihy, Katharine 2008

机译：2型糖尿病患者的情绪负担与血糖控制之间的关系以及口服抗糖尿病药，联合疗法，降钙素模拟物和胰岛素治疗的个体之间情绪负担和血糖控制的差异
6. Erratum. Benefits of LixiLan a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 [O] . Julio Rosenstock, Ronnie Aronson, George Grunberger, 2017

机译：勘误表。 LixiLan（一种可滴定比例的固定剂量组合胰岛素甘精胰岛素和Lixisenatide相对于胰岛素Glargine和Lixisenatide单组分在口服药物控制不充分的情况下的益处）：LixiLan-O随机试验。 2016年糖尿病护理； 39：2026-2035
7. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial [O] . Julio Rosenstock, Michaela Diamant, Vanita R. Aroda, 2016

机译：Lixilan的功效和安全性，Lixisenatide和胰岛素狼甘蓝的滴定定义组合，与2型糖尿病患者在二甲双胍单疗法上不充分控制：Lixilan概念的随机试验

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

著录项

相似文献

相关主题

期刊订阅